Surmodics, Inc. (NASDAQ:SRDX) Shares Sold by Olympiad Research LP

Olympiad Research LP lessened its stake in Surmodics, Inc. (NASDAQ:SRDX) by 82.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,464 shares of the company’s stock after selling 40,127 shares during the quarter. Olympiad Research LP owned 0.06% of Surmodics worth $335,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of SRDX. Oddo BHF Asset Management Sas acquired a new position in shares of Surmodics in the 3rd quarter valued at about $6,593,000. Phocas Financial Corp. acquired a new position in shares of Surmodics in the 3rd quarter valued at about $3,430,000. State Street Corp lifted its holdings in shares of Surmodics by 19.2% in the 3rd quarter. State Street Corp now owns 374,068 shares of the company’s stock valued at $14,506,000 after buying an additional 60,240 shares during the period. Murchinson Ltd. acquired a new position in shares of Surmodics in the 3rd quarter valued at about $2,133,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Surmodics in the 3rd quarter valued at about $1,190,000. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Price Performance

NASDAQ:SRDX opened at $34.85 on Friday. Surmodics, Inc. has a 12 month low of $25.17 and a 12 month high of $42.44. The stock has a 50 day moving average of $37.02 and a two-hundred day moving average of $38.36. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The firm has a market cap of $498.36 million, a P/E ratio of -34.50 and a beta of 1.20.

Surmodics (NASDAQ:SRDX) last posted its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. On average, analysts expect that Surmodics, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SRDX. StockNews.com began coverage on Surmodics in a research note on Monday, February 3rd. They issued a “hold” rating for the company. Needham & Company LLC restated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $50.00.

Insiders Place Their Bets

In other news, CFO Timothy J. Arens sold 7,009 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the completion of the sale, the chief financial officer now directly owns 70,350 shares in the company, valued at $2,774,604. This represents a 9.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.90% of the stock is owned by company insiders.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).